This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in the United States.
This study is looking at examine feasibility, acceptance, and impact of OSA treatment and how it affects cognitive function in people with SMI for people with schizoaffective disorder, Schizophrenia, bipolarity, or Obstructive Sleep Apnea of. Taking part may give some people access to Automatic Positive Airway Pressure (APAP), but direct benefit is not guaranteed.
The official record suggests in-person participation through a lab, with sites including UCSD in La Jolla. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
This study may matter because it is evaluating Automatic Positive Airway Pressure (APAP) in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by University of California, San Diego. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.